Read by QxMD icon Read

Journal of Viral Hepatitis

Lai Wei, Dong Chen, Bo Zhang, Yuanyuan Zhao, Bin Liu, Huibo Shi, Fanjun Zeng, Changsheng Ming, Jipin Jiang, Dunfeng Du, Zhishui Chen
Due to the severe shortage of the donor pool in China, a large number of patients are waiting for a suitable liver, or even worse lose the opportunity of transplantation. Reasonable use of hepatitis B surface antigen-positive (HBsAg-positive) donors is one possible strategy to increase the donor pool but the long term outcome in a Chinese population is unknown. To evaluate the safety of using of HBsAg-positive donor for liver transplantation, we set up a multicentric retrospective study from January 1, 2007 to December 31, 2012...
July 15, 2018: Journal of Viral Hepatitis
Byung Gyu Kim, Neung Hwa Park, Seung Bum Lee, Hojune Lee, Byung Uk Lee, Jae Ho Park, Seok Won Jung, In Du Jeong, Sung-Jo Bang, Jung Woo Shin
Few studies have directly compared the long-term clinical outcomes of entecavir (ETV) and tenofovir disoproxil fumarate (TDF). This study aimed to compare the risk of mortality, liver transplantation, and hepatic complications including hepatocellular carcinoma (HCC) and hepatic decompensation between these drugs in treatment-naïve chronic hepatitis B (CHB). We performed a longitudinal observational analysis of data from 1325 consecutive adult CHB patients with a cumulative adherence of ≥80% to treatment with ETV (n=721) or TDF (n=604) at a tertiary referral hospital in Ulsan, Korea, from January 1, 2007, through April 31, 2017...
July 11, 2018: Journal of Viral Hepatitis
Motonobu Nomura, Masataka Tsuge, Takuro Uchida, Nobuhiko Hiraga, Mio Kurihara, Ken Tsushima, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Hiromi Abe-Chayama, Tomokazu Kawaoka, Daiki Miki, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Yizhou Zhang, Grace Naswa Makokha, C Nelson Hayes, Shinji Tanaka, Kazuaki Chayama
The activation of hepatitis B virus (HBV)-related hepatitis is associated with both natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). We analyzed the association between the immune response and changes in the proportion of Pre-S deletion variants. We quantified Pre-S deleted HBV (HBV-del) and wild type HBV (HBV-wt) DNA levels in sera obtained from HBV-infected mice and chronic hepatitis B patients. In chronic hepatitis B patients, the HBV-del proportion usually increased during or after ALT elevation but did not occur during all ALT elevations...
July 11, 2018: Journal of Viral Hepatitis
Martin Kåberg, Georg Navér, Anders Hammarberg, Ola Weiland
The major transmission route for HCV is through sharing of unsterile injection equipment among people who inject drugs (PWID). The WHO strategy for HCV elimination by 2030 proposes increased efforts to treat PWID populations that drive the HCV epidemic. Among participants in the Stockholm needle exchange program (NEP), the HCV prevalence is 60%. We aimed to study HCV incidence, spontaneous HCV clearance rate, and predictors associated with new HCV infections and reinfections in NEP participants. All 2320 patients enrolled in the program between 8th of April 2013 and 23rd of September 2016 were tested for HCV at baseline, and responded to a questionnaire regarding sociodemographic data and injection risk behaviour...
July 11, 2018: Journal of Viral Hepatitis
Kazuhiko Hayashi, Masatoshi Ishigami, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Yoshiki Hirooka, Hidenori Toyoda, Takashi Kumada, Masashi Hattori, Yoshiaki Katano, Hidemi Goto
The optimal term of follow-up for patients who achieve sustained virological responses (SVR) is an important topic because of the wide spread use of direct-acting antivirals (DAA), which achieve a high SVR rate. Investigations of long-term follow-up among patients with SVR after interferon (IFN) therapy have reported that approximately 80-100% of patients maintained SVR. However, the long term durability of SVR to DAA treatment is unknown. The aim of the present study was to evaluate the incidence of late relapse in patients who achieved SVR with daclatasvir (DCV) and asunaprevir (ASV)...
July 11, 2018: Journal of Viral Hepatitis
Xiaomei Yue, Tingyu Yang, Yao Zhao
First, we thank Dr. Zhou for his interest in our study. Dr. Zhou thought that "based on decline or loss of anti-HBs in children, a conclusion that revaccination against hepatitis B in children is required is not scientifically and unnecessary revaccination is wasteful and should be avoided because of the potential adverse events, although very rare", regretfully we disagree this statement. The Global Advisory Committee on Vaccine Safety (GACVS) has confirmed the excellent safety profile of hepatitis B vaccine...
July 11, 2018: Journal of Viral Hepatitis
Zobair M Younossi, Maria Stepanova, Linda Henry, Kwang-Hyub Han, Sang Hoon Ahn, Young-Suk Lim, Wan-Long Chuang, Jia-Horng Kao, Kinh Van Nguyen, Ching Lung Lai, Henry Lik-Yuen Chan, Lai Wei
Although HCV infection is highly prevalent in East Asia, these patients have been underrepresented in HRQL studies. Here we assess HRQL in East Asian HCV patients treated with different anti-HCV regimens. Patients completed Short Form-36 (SF-36) before, during and after treatment. A total of 989 HCV patients were enrolled in two phase 3 clinical trials [China: 60.2%, South Korea: 22.4%, Taiwan: 17.4%; genotype 1: 55.3%, treatment-naïve: 57.5%; cirrhosis: 14.0%]. Patients received pegylated interferon, sofosbuvir, and ribavirin (Peg-IFN+SOF+RBV; n=130, genotypes 1, 6) or SOF+RBV (n=475, all genotypes) or SOF and ledipasvir (LDV/SOF; n=384, genotype 1)...
July 4, 2018: Journal of Viral Hepatitis
Zameer Mohamed, John Rwegasha, Jin U Kim, Yusuke Shimakawa, Lila Poiteau, Stéphane Chevaliez, Sanjay Bhagani, Simon D Taylor-Robinson, Mark R Thursz, Jessie Mbwambo, Maud Lemoine
The World Health Organisation has recently called for hepatitis C virus (HCV) elimination and has identified people who inject drugs (PWID) as a key population to scale-up screening and linkage to care. This study reports the cascade of care for HCV in PWID attending the largest opioid substitution treatment (OST) clinic in Dar-es-Salaam, Tanzania. Between February 2011 and March 2016, HCV serology for all PWID registered at the Muhimbili National Hospital OST clinic, Dar-es-Salaam were obtained from records...
July 3, 2018: Journal of Viral Hepatitis
Yao Liu, Ci Song, Hengli Ni, Weijuan Jiao, Wenjuan Gan, Xiaoqiang Dong, Jibin Liu, Liguo Zhu, Xiangjun Zhai, Zhibin Hu, Jianming Li
Previously, we identified UBE2L3 as a susceptibility gene for chronic hepatitis B virus (HBV) infection through genome-wide association study. Here we analyzed the association between genetic variants of UBE2L3 and the susceptibility to HBV-related hepatocellular carcinoma (HCC) and further explored its role in HCC. This case-controlled study included 1344 subjects who cleared HBV, 1506 HBV carriers and 1057 HBV-related HCC patients. Two single nucleotide polymorphisms (SNPs) were genotyped, including rs2266959 and rs4821116...
July 3, 2018: Journal of Viral Hepatitis
Jing Tan, Xuanyue Mao, Guiting Zhang, Wen Wang, Tianying Pan, Xinghui Liu, Xin Sun
Chronic hepatitis B virus (HBV) infection is a prevalent public health issue worldwide. Its impact on important pregnancy outcomes, such as gestational diabetes mellitus (GDM), has not been clearly established. The findings from published studies are inconsistent. In this systematic review and meta-analysis, we aimed to clarify whether HBV infection manifested during pregnancy is associated with increased risk of GDM. We searched Medline and EMBASE for cohort studies and case-control studies that investigated the association between maternal HBsAg positivity and GDM...
July 3, 2018: Journal of Viral Hepatitis
Nadeem Anwar, Kenneth E Sherman
Liver transplant centers throughout the United States face a huge shortage of liver organs for their wait-listed patients. Various types of innovations are being considered for expansion of this donor pool. Organs that were previously deemd to be high risk are now being considered for transplantation. For the last 25 years, Hepatitis B core Antibody (anti-HBc+) organs have been used for liver transplantation. While the initial transplantations did reveal a high incidence of De Novo Hepatitis (DNH) in the recipients, the medical knowledge and experience have evolved and this risk has been markedly decreased...
July 3, 2018: Journal of Viral Hepatitis
Y-H Hsieh, A V Patel, G S Loevinsohn, D L Thomas, R E Rothman
No abstract text is available yet for this article.
June 11, 2018: Journal of Viral Hepatitis
R Kumar
No abstract text is available yet for this article.
June 11, 2018: Journal of Viral Hepatitis
A Shi, X Zhang, F Xiao, L Zhu, W Yan, M Han, X Luo, T Chen, Q Ning
HBV surface antigen (HBsAg) reduction is well observed in chronic hepatitis B (CHB) patients treated with pegylated interferon alpha-2a (PegIFNα). However, the mechanism of HBsAg suppression has not been fully elucidated. Twenty-seven of 55 entecavir-treated CHB e antigen positive patients were switched to PegIFNα treatment (Group A) whereas 28 patients continued entecavir treatment (Group B). The percentage or absolute number of CD56bright /CD56dim NK cells, expression of receptors and cytokines were evaluated by flow cytometry for 48 weeks and correlated with treatment efficacy...
June 11, 2018: Journal of Viral Hepatitis
T-C Zhou, X Li, L-J Chen, J-H Fan, X Lai, Y Tang, L Zhang, J Wei
CircRNAs exert gene regulatory effects by sequestering target microRNAs (miRNAs) and play a vital role in the onset and development of disease. Until recently, little has been known about the expression, regulation and biological function of circRNAs in both health and chronic hepatitis B (CHB).To identify hepatic circRNAs associated with CHB, we performed RNA sequencing using liver biopsies from untreated CHB patients and controls. We then established a bioinformatics pipeline for identification of CHB-associated circRNAs and in silico analysis of the circRNA-miRNA-mRNA pathways...
June 11, 2018: Journal of Viral Hepatitis
G L Lutterkort, A Wranke, J Hengst, C Yurdaydin, J Stift, B Bremer, S Hardtke, O Keskin, R Idilman, M P Manns, H P Dienes, C Falk, H Wedemeyer, B Heidrich
Chronic hepatitis D is caused by coinfection of hepatitis B and hepatitis D virus. While HDV is the dominant virus over HBV in the majority of cases, mechanisms and consequences of viral dominance are largely unknown. We aimed to investigate associations between viral dominance patterns and patients' characteristics and inflammatory features; 109 HDV-infected patients treated with PEG-IFNa-2α within the international multicentre, prospective HIDIT-2 trial were studied. Patients were classified as D- or B-dominant if the viral load of one virus exceeded that of the other virus by more than 1log10 ...
June 11, 2018: Journal of Viral Hepatitis
R Flisiak, E Janczewska, M Łucejko, E Karpińska, D Zarębska-Michaluk, K Nazzal, B Bolewska, J Białkowska, H Berak, K Fleischer-Stępniewska, K Tomasiewicz, K Karwowska, K Simon, A Piekarska, O Tronina, E Tuchendler, A Garlicki
We followed for 2 years patients treated with direct-acting agents (DAA) to assess long-term durability of virologic response, improvement of liver function, reduction in liver stiffness (LS) and risk of hepatocellular carcinoma (HCC). The study included patients from 16 hepatologic centres involved in the AMBER, investigator-initiated study on treatment of chronic hepatitis C patients within a programme preceding EU registration of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin. A total of 204 patients among 209 from the primary study were enrolled, 200 with available testing at 2-year follow-up (2yFU) with undetectable HCV RNA (198 responders and 2 nonresponders retreated)...
June 11, 2018: Journal of Viral Hepatitis
J Haridy, A Wigg, K Muller, J Ramachandran, E Tilley, V Waddell, D Gordon, D Shaw, D Huynh, J Stewart, R Nelson, M Warner, M Boyd, M A Chinnaratha, D Harding, L Ralton, A Colman, D Liew, G Iyngkaran, E Tse
In March 2016, the Australian government offered unrestricted access to direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) to the entire population. This included prescription by any medical practitioner in consultation with specialists until sufficient experience was attained. We sought to determine the outcomes and experience over the first twelve months for the entire state of South Australia. We performed a prospective, observational study following outcomes of all treatments associated with the state's four main tertiary centres...
June 11, 2018: Journal of Viral Hepatitis
Z Liu, Q Yang, O Shi, W Ye, X Chen, T Zhang
Viral hepatitis is a major public health concern in China, but data on national epidemiological characteristics are lacking. We collected reporting incidence data on hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in China from 2004 to 2014. Empirical mode decomposition (EMD) was performed to accurately describe the reporting incidence trends of HBV and HCV. A mathematical model was used to estimate the relative change in incidence across provinces and age groups. Nationwide, a total of 916 426 hepatitis B cases and 39 381 hepatitis C cases were recorded in 2004; the reporting incidences of HBV and HCV were 70...
May 31, 2018: Journal of Viral Hepatitis
J R Kramer, A Puenpatom, K F Erickson, Y Cao, D Smith, H B El-Serag, F Kanwal
Elbasvir/grazoprevir (EBR/GZR) is an all-oral direct-acting antiviral agent (DAA) with high sustained virologic response (SVR) in clinical trials. This study's primary objective was to evaluate effectiveness of EBR/GZR among HCV-infected patients in a real-world clinical setting. We conducted a nationwide retrospective observational cohort study of HCV-infected patients in the US Department of Veterans Affairs (VA) using the VA Corporate Data Warehouse. The study population included patients with positive HCV RNA who initiated EBR/GZR from February 1 to August 1, 2016...
May 31, 2018: Journal of Viral Hepatitis
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"